BRPI0517921A - métodos para preparar compostos de indazol - Google Patents
métodos para preparar compostos de indazolInfo
- Publication number
- BRPI0517921A BRPI0517921A BRPI0517921-1A BRPI0517921A BRPI0517921A BR PI0517921 A BRPI0517921 A BR PI0517921A BR PI0517921 A BRPI0517921 A BR PI0517921A BR PI0517921 A BRPI0517921 A BR PI0517921A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compounds
- preparing
- indazole compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
MéTODOS PARA PREPARAR COMPOSTOS DE INDAZOL. A presente invenção refere-se aos métodos para a preparação de compostos de indazol tendo a fórmula (I) ou sais farmaceuticamente aceitáveis ou solvatos dos mesmos. Os compostos da fórmula (I) são úteis como agentes antiangiogênicos e como agentes para a modulação e/ou inibição da atividade de proteína cinases, portanto provendo os tratamentos para o câncer ou outras doenças associadas com a proliferação celular mediada por proteína cinases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62457504P | 2004-11-02 | 2004-11-02 | |
PCT/IB2005/003300 WO2006048745A1 (en) | 2004-11-02 | 2005-10-21 | Methods for preparing indazole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0517921A true BRPI0517921A (pt) | 2008-10-21 |
Family
ID=35528034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517921-1A BRPI0517921A (pt) | 2004-11-02 | 2005-10-21 | métodos para preparar compostos de indazol |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1809625A1 (pt) |
JP (1) | JP2008518901A (pt) |
KR (1) | KR20070058689A (pt) |
CN (1) | CN101044138A (pt) |
AR (1) | AR051753A1 (pt) |
AU (1) | AU2005300311A1 (pt) |
BR (1) | BRPI0517921A (pt) |
CA (1) | CA2586176A1 (pt) |
IL (1) | IL182096A0 (pt) |
MX (1) | MX2007003603A (pt) |
NO (1) | NO20072747L (pt) |
RU (1) | RU2007114112A (pt) |
TW (1) | TW200614990A (pt) |
WO (1) | WO2006048745A1 (pt) |
ZA (1) | ZA200702317B (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP3252047B1 (en) | 2007-04-05 | 2022-05-11 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals |
EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
EP2163544A1 (en) * | 2008-09-16 | 2010-03-17 | Pfizer, Inc. | Methods of preparing indazole compounds |
CN103826618A (zh) | 2011-09-30 | 2014-05-28 | 辉瑞大药厂 | N-甲基-2-[3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基]苯甲酰胺的药物组合物 |
JP2014533262A (ja) | 2011-11-11 | 2014-12-11 | ファイザー・インク | 慢性骨髄性白血病を治療するためのn−メチル−2−[3−((e)−2−ピリジン−2−イル−ビニル)−1h−インダゾール−6−イルスルファニル]−ベンズアミド |
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
CN103387565B (zh) * | 2013-07-29 | 2014-10-29 | 苏州明锐医药科技有限公司 | 阿西替尼的制备方法 |
CN103570696B (zh) * | 2013-11-06 | 2016-02-24 | 湖南欧亚生物有限公司 | 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用 |
WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
US10570202B2 (en) | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
EP3127900B1 (en) * | 2014-03-31 | 2017-10-18 | Senju Pharmaceutical Co., Ltd. | Alkynyl indazole derivative and use thereof |
CN104072484B (zh) * | 2014-07-07 | 2016-07-06 | 渤海大学 | 氮-(4-(芳巯基)-1氢-吲唑-3-基)-1-(芳杂环取代)甲基亚胺类化合物及其药学上可接受的盐及其制备方法和应用 |
WO2016032927A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
CN112263677A (zh) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
US9580406B2 (en) | 2015-04-28 | 2017-02-28 | Signa S.A. De C.V. | Processes for the preparation of axitinib |
US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
AU2017339856A1 (en) | 2016-10-06 | 2019-05-23 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
US20220194921A1 (en) | 2019-04-18 | 2022-06-23 | Synthon B.V. | Process for preparation of axitinib |
CN112209861A (zh) * | 2019-07-11 | 2021-01-12 | 鲁南制药集团股份有限公司 | 一种阿昔替尼中间体化合物及其制备方法 |
CN112442010B (zh) * | 2019-08-30 | 2023-10-03 | 润佳(苏州)医药科技有限公司 | 一类前药化合物及其在治疗癌症方面的应用 |
CN111440102B (zh) * | 2020-04-26 | 2022-02-15 | 大连凯飞化学股份有限公司 | 一种二硫代二苯甲酰胺类化合物的制备方法 |
US20240117030A1 (en) | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
CN114591338B (zh) * | 2022-03-31 | 2023-05-09 | 苏州欧康维视生物科技有限公司 | 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
CA2510850A1 (en) * | 2002-12-19 | 2004-07-08 | Pfizer Inc. | 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
WO2004078116A2 (en) * | 2003-03-03 | 2004-09-16 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
WO2005094823A1 (ja) * | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | Flt-3阻害剤 |
-
2005
- 2005-10-21 AU AU2005300311A patent/AU2005300311A1/en not_active Abandoned
- 2005-10-21 KR KR1020077009804A patent/KR20070058689A/ko not_active Application Discontinuation
- 2005-10-21 MX MX2007003603A patent/MX2007003603A/es unknown
- 2005-10-21 EP EP05796299A patent/EP1809625A1/en not_active Withdrawn
- 2005-10-21 JP JP2007538538A patent/JP2008518901A/ja not_active Withdrawn
- 2005-10-21 RU RU2007114112/04A patent/RU2007114112A/ru not_active Application Discontinuation
- 2005-10-21 CN CNA2005800361530A patent/CN101044138A/zh active Pending
- 2005-10-21 WO PCT/IB2005/003300 patent/WO2006048745A1/en active Application Filing
- 2005-10-21 BR BRPI0517921-1A patent/BRPI0517921A/pt not_active IP Right Cessation
- 2005-10-21 CA CA002586176A patent/CA2586176A1/en not_active Abandoned
- 2005-11-01 TW TW094138224A patent/TW200614990A/zh unknown
- 2005-11-01 AR ARP050104567A patent/AR051753A1/es not_active Application Discontinuation
-
2007
- 2007-03-20 ZA ZA200702317A patent/ZA200702317B/xx unknown
- 2007-03-21 IL IL182096A patent/IL182096A0/en unknown
- 2007-05-30 NO NO20072747A patent/NO20072747L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR051753A1 (es) | 2007-02-07 |
JP2008518901A (ja) | 2008-06-05 |
NO20072747L (no) | 2007-07-31 |
CN101044138A (zh) | 2007-09-26 |
ZA200702317B (en) | 2008-09-25 |
RU2007114112A (ru) | 2008-12-10 |
WO2006048745A1 (en) | 2006-05-11 |
KR20070058689A (ko) | 2007-06-08 |
TW200614990A (en) | 2006-05-16 |
CA2586176A1 (en) | 2006-05-11 |
IL182096A0 (en) | 2007-07-24 |
MX2007003603A (es) | 2007-05-21 |
EP1809625A1 (en) | 2007-07-25 |
AU2005300311A1 (en) | 2006-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517921A (pt) | métodos para preparar compostos de indazol | |
BRPI0410563A (pt) | derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
BR112022002532A2 (pt) | Compostos heterocíclicos como inibidores de quinase | |
BRPI0713555A2 (pt) | ciclopenta [d] pirimidinas como inibidores de akt protéina cinase | |
BR0208373A (pt) | Inibidores da tirosina cinase | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
BR0308030A (pt) | Derivados de 5-feniltiazol e uso como inibidores de pi3 cinase | |
UA94097C2 (ru) | Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ | |
ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
TW200833693A (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
UY29591A1 (es) | Aminopirimidinas como moduladores de quinasas | |
DOP2005000014A (es) | Derivados 1h-tieno[2, 3-c] pirazol utiles como inhibidores de quinasa | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
ATE493418T1 (de) | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren | |
BRPI0611964A2 (pt) | moduladores de alquilquinolina e alquilquinazolina cinase | |
BRPI0411868A (pt) | derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase | |
BRPI0410633A (pt) | piridopirazinas e uso das mesmas como moduladores de cinase | |
BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |